Profile data is unavailable for this security.
About the company
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
- Revenue in USD (TTM)0.00
- Net income in USD-25.24m
- Incorporated2016
- Employees35.00
- LocationKiromic Biopharma Inc7707 Fannin St., Suite 140HOUSTON 77054United StatesUSA
- Phone+1 (832) 968-4888
- Fax+1 (302) 655-5049
- Websitehttps://kiromic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galmed Pharmaceuticals Ltd | 0.00 | -6.36m | 2.00m | 3.00 | -- | 0.1479 | -- | -- | -2.83 | -2.83 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | -43.37 | -45.06 | -51.38 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 2.03m | 15.00 | -- | 0.1026 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 2.03m | 8.00 | -- | 0.3628 | -- | -- | -33.43 | -33.43 | 0.00 | 10.98 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 2.11m | 0.00 | -- | 1.18 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 2.17m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.15m | 2.18m | 6.00 | -- | 1.76 | -- | -- | -11.19 | -11.19 | 0.00 | 0.1594 | 0.00 | -- | -- | 0.00 | -474.77 | -755.77 | -781.78 | -- | -- | -- | -- | -- | -- | -3,015.03 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -25.24m | 2.31m | 35.00 | -- | -- | -- | -- | -21.18 | -21.18 | 0.00 | -5.60 | 0.00 | -- | -- | 0.00 | -169.39 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -8.20 | 2.45 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 2.49m | 12.00 | -- | -- | -- | 5.54 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.55m | 2.00 | -- | 0.3613 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -7.18m | 2.56m | 3.00 | -- | 0.5661 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -8.96m | 2.60m | 9.00 | -- | 0.2741 | -- | -- | -32.09 | -32.09 | 0.00 | 5.80 | 0.00 | -- | -- | 0.00 | -54.61 | -- | -91.95 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors Global LPas of 15 May 2024 | 171.19k | 11.10% |
| Sabby Management LLCas of 31 Dec 2023 | 0.00 | 0.00% |
